伊布替尼灭活B淋巴细胞可限制小鼠子宫内膜异位症进展
该研究在小鼠同种异体子宫内膜移植模型中比较了抗CD20抗体清除B细胞与Bruton酪氨酸激酶(Btk)抑制剂伊布替尼灭活B细胞对子宫内膜异位症进展的影响,观察21天。结果显示伊布替尼可阻止病灶生长、降低病灶环氧化酶-2、α平滑肌肌动蛋白和I型胶原mRNA表达,并使活化的B细胞向调节性B细胞偏移;而抗CD20抗体清除B细胞对病灶无影响。
要点
- 伊布替尼通过Btk抑制使活化B细胞向调节性B细胞偏移,阻止小鼠子宫内膜异位病灶生长。
- 抗CD20抗体清除B细胞对小鼠子宫内膜异位病灶的活动和生长无影响。
- 伊布替尼组腹腔M2巨噬细胞数量较抗CD20组和对照组减少。
核心结论
- 使用伊布替尼抑制Btk使活化B细胞向调节性B细胞偏移可阻止小鼠子宫内膜异位症进展,而使用抗CD20抗体清除B细胞无此效果。
- 抗CD20或伊布替尼能否预防人类子宫内膜异位症的发生和(或)进展仍不清楚。
研究设计与样本
- 研究比较对照小鼠与接受抗CD20清除抗体或Btk抑制剂伊布替尼(阻止B细胞活化)治疗的小鼠,观察子宫内膜异位症进展21天。
- 同种异体子宫内膜移植后,通过病灶体积、重量、超声、组织学和病灶靶基因表达比较治疗组与对照组小鼠。
- 对分离的脾细胞和腹腔细胞用流式细胞术进行活化B细胞、调节性B细胞、T淋巴细胞和巨噬细胞表型分析,用ELISA检测细胞因子。
主要发现
- Btk抑制剂伊布替尼阻止病灶生长,降低病灶中环氧化酶-2、α平滑肌肌动蛋白和I型胶原mRNA表达,并使子宫内膜异位症小鼠脾和腹腔中活化B细胞向调节性B细胞偏移。
- 伊布替尼治疗小鼠腹腔M2巨噬细胞数量较抗CD20组和对照组减少。
- 与对照组相比,抗CD20抗体清除B细胞对子宫内膜异位病灶的活动和生长无影响,对巨噬细胞也无影响。
局限性
- 尚不清楚抗CD20清除B细胞或伊布替尼灭活B细胞能否预防人类子宫内膜异位症的发生和(或)进展。
- 需进一步研究以阐明B细胞亚群在人类子宫内膜异位症中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the effects of B lymphocyte inactivation or depletion on the progression of endometriosis? SUMMARY ANSWER: Skewing activated B cells toward regulatory B cells (Bregs) by Bruton's tyrosine kinase (Btk) inhibition using Ibrutinib prevents endometriosis progression in mice while B cell depletion using an anti-CD20 antibody has no effect. WHAT IS KNOWN ALREADY: A polyclonal activation of B cells and the presence of anti-endometrial autoantibodies have been described in a large proportion of women with endometriosis though their exact role in the disease mechanisms remains unclear. STUDY DESIGN, SIZE, DURATION: This study included comparison of endometriosis progression for 21 days in control mice versus animals treated with the anti-CD20 depleting antibody or with the Btk inhibitor Ibrutinib that prevents B cell activation. PARTICIPANTS/MATERIALS, SETTING, METHODS: After syngeneic endometrial transplantation, murine endometriotic lesions were compared between treated and control mice using volume, weight, ultrasonography, histology and target genes expression in lesions. Phenotyping of activated and regulatory B cells, T lymphocytes and macrophages was performed by flow cytometry on isolated spleen and peritoneal cells. Cytokines were assayed by ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Btk inhibitor Ibrutinib prevented lesion growth, reduced mRNA expression of cyclooxygenase-2, alpha smooth muscle actin and type I collagen in the lesions and skewed activated B cells toward Bregs in the spleen and peritoneal cavity of mice with endometriosis. In addition, the number of M2 macrophages decreased in the peritoneal cavity of Ibrutinib-treated mice compared to anti-CD20 and control mice. Depletion of B cells using an anti-CD20 antibody had no effect on activity and growth of endometriotic lesions and neither on the macrophages, compared to control mice. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: It is still unclear whether B cell depletion by the anti-CD20 or inactivation by Ibrutinib can prevent establishment and/or progression of endometriosis in humans. WIDER IMPLICATIONS OF THE FINDINGS: Further investigation may contribute to clarifying the role of B cell subsets in human endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant of Institut National de la Santé et de la Recherche Médicale and Paris Descartes University. None of the authors has any conflict of interest to disclose.
引用
- Riccio LGC, Jeljeli M, Santulli P, et al. B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice. Hum Reprod. 2019. PMID: 31247078. doi:10.1093/humrep/dez071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。